There were 691 press releases posted in the last 24 hours and 158,505 in the last 365 days.

Global Anticoagulants Market to Grow at a CAGR Of 8.59% to Forecast 2020

Global Anticoagulants Market to Grow at a CAGR Of 4.64% to Forecast 2020

PUNE, INDIA , November 16, 2016 /EINPresswire.com/ -- Global Anticoagulants Market

The Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

According to DelveInsight, Global Anticoagulants Market to Grow at a CAGR Of 4.64% to Forecast 2020

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476538-anticoagulants-market-insights-drugs-sales-forecast-vte-af-2020

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke. Globally the overall incidence for Venous Thromboembolism (VTE) and Atrial fibrillation (AF) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease and AF affects approximately 3 million patients in the US, and over 6.7 million in the US and Europe combined.

Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
• Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
• To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.

Access Complete Report @ https://www.wiseguyreports.com/reports/476538-anticoagulants-market-insights-drugs-sales-forecast-vte-af-2020

Scope of the Report:

• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Table of Contents
Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Venous Thromboembolism
Disease Overview
Epidemiology of Venous Thromboembolism
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Atrial Fibrillation
Disease Overview
Epidemiology of Atrial Fibrillation
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 4 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 5 Anticoagulants Market Assessment
Key Findings
Global Anticoagulants Sales
Global Anticoagulants Market by Drugs
Global Anticoagulants Market Share (%)
Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
Global Anticoagulants Market Share (%) in Atrial Fibrillation
Global Anticoagulants Market Sales by Venous Thromboembolism
Global Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 6 United States Anticoagulants Market Assessment
Key Findings
United States Anticoagulants Market
United States Anticoagulants Market Share (%)
United States Anticoagulants Market Sales by Atrial Fibrillation
United States Anticoagulants Market Share (%) in Atrial Fibrillation
United States Anticoagulants Market Sales by Venous Thromboembolism
United States Anticoagulants Market Share (%) in Venous
Thromboembolism
Chapter 8 Europe 5 Anticoagulants Market Assessment
Key Findings
Europe 5 Anticoagulants Market
Europe 5 Anticoagulants Market Share (%)
Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 10 Japan Anticoagulants Market Assessment
Key Findings
Japan Anticoagulants Market
Japan Anticoagulants Market Share (%)
Japan Anticoagulants Market Sales by Atrial Fibrillation
Japan Anticoagulants Market Share (%) in Atrial Fibrillation
Japan Anticoagulants Market Sales by Venous Thromboembolism
Japan Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 12 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 13 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 15 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 16 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)

Continued....

Buy Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476538

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here